Neuland Laboratories cash flow

Latest FY26

Cash from operations: ₹347cr+9.2% on FY25
Capital spending: ₹396cr+91.8% on FY25
Free cash flow: −₹49.4cr₹111 cr in FY25
Cash from financing: ₹21.0cr−16.0% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	91.7	65.5	59.7	52.8
	—	23.9	8.3	14.0	13.1
	—	−10.1	−10.6	−8.2	−1.6
	—	0.0	−7.7	0.0	0.0
	—	1.3	−0.2	−3.5	8.1
	—	−4.3	−67.4	0.2	−1.0
	—	−125	−35.3	−71.2	−14.0
	—	−224	54.9	−8.7	−134
	—	−0.7	−1.9	4.5	−2.7
	—	−7.2	2.5	−1.2	−1.9
	—	−2.9	8.4	−23.9	−0.3
	—	0.1	0.0	1.5	0.0
	—	−0.0	0.0	0.0	0.0
	—	16.1	58.8	20.3	54.4
	—	19.1	−22.9	41.9	17.4
	—	174	−6.2	−52.0	70.6
	—	0.0	0.0	−0.0	0.0
	—	0.2	−0.5	0.1	4.7
	—	8.7	0.0	−2.1	0.0
Cash from operating activities
	669	489	346	401	216
	—	−38.8	45.8	−28.7	65.1
	—	450	392	373	281
	—	104	74.7	112	43.6
	—	347	317	261	237
Cash from investing activities
	—	390	206	141	65.7
	—	5.9	0.0	2.2	0.4
	—	0.9	1.2	1.3	1.5
	—	1.1	0.0	0.0	0.0
	—	0.0	95.4	0.0	0.0
	—	150	0.0	0.0	0.0
	—	265	0.0	0.0	0.0
	—	8.6	9.3	7.9	1.5
	—	−151	−198	−15.2	1.6
	—	−424	−298	−150	−61.5
Cash from financing activities
	—	106	94.8	8.8	3.1
	—	44.7	39.4	48.3	117
	—	7.5	5.4	3.6	3.5
	—	17.0	7.0	13.4	12.3
	—	15.4	18.0	12.8	6.4
	—	21.0	25.0	−69.3	−136
	—	−56.1	44.2	42.2	39.9
	—	0.8	0.2	0.0	0.0
	—	−55.3	44.4	42.2	39.9
	—	76.7	—	87.6	45.4
Reference items
	763	574	323	463	272
	32.2%	28.4%	21.9%	29.7%	22.8%
	−49.4	−49.4	111	118	171
	—	−5.8	157	65.1	—
	−₹38.27	−₹38.27	₹85.98	₹91.09	₹132.62
	—	0.95×	1.22×	0.87×	1.45×
	—	104	74.7	112	43.6
	—	17.0	7.0	13.4	12.3

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

NEULANDLAB₹19,970.00

Neuland Laboratories Ltd.

· Pharma & Health

₹ CrorePeersDIVISLAB LAURUSLABS NH NATCOPHARM LALPATHLAB SAILIFE COHANCE ASTERDMMcap ₹25,762 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	52.8	59.7	65.5	91.7	—
+ Finance Costs	13.1	14.0	8.3	23.9	—
+ Interest Income	-1.6	-8.2	-10.6	-10.1	—
+ Fair Value (Gains) / Losses	0.0	0.0	-7.7	0.0	—
+ Unrealised FX (Gain) / Loss	8.1	-3.5	-0.2	1.3	—
+ Other Non-cash Items	-1.0	0.2	-67.4	-4.3	—
Changes in Working Capital
+ Inventories	-14.0	-71.2	-35.3	-124.5	—
+ Trade Receivables — Current	-134.3	-8.7	54.9	-224.2	—
+ Other Financial Assets — Current	-2.7	4.5	-1.9	-0.7	—
+ Other Financial Assets — Non-current	-1.9	-1.2	2.5	-7.2	—
+ Other Current Assets	-0.3	-23.9	8.4	-2.9	—
+ Other Non-current Assets	0.0	1.5	0.0	0.1	—
+ Other Bank Balances	0.0	0.0	0.0	-0.0	—
+ Trade Payables — Current	54.4	20.3	58.8	16.1	—
+ Other Financial Liabilities — Current	17.4	41.9	-22.9	19.1	—
+ Other Current Liabilities	70.6	-52.0	-6.2	173.9	—
+ Other Non-current Liabilities	0.0	-0.0	0.0	0.0	—
+ Provisions — Current	4.7	0.1	-0.5	0.2	—
+ Provisions — Non-current	0.0	-2.1	0.0	8.7	—
Cash from Operating Activities
Profit Before Tax (per I/S)	215.7	401.4	346.3	489.0	669.3
+ Total Adjustments (incl. Working Capital)	65.1	-28.7	45.8	-38.8	—
Cash from Operations (pre-tax)	280.8	372.8	392.1	450.2	—
+ Income Taxes Paid	43.6	111.6	74.7	103.5	—
Cash from Operating Activities	237.2	261.2	317.4	346.7	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	65.7	141.5	206.5	390.2	—
+ Acq of Intangible Assets	0.4	2.2	0.0	5.9	—
+ Disp of Fixed Assets	1.5	1.3	1.2	0.9	—
+ Acq of Intangibles under Development	0.0	0.0	0.0	1.1	—
+ Disp of Investment Property	0.0	0.0	95.4	0.0	—
+ Acq of Other Long-term Assets	0.0	0.0	0.0	150.0	—
+ Disp of Other Long-term Assets	0.0	0.0	0.0	265.2	—
+ Interest Received — Investing	1.5	7.9	9.3	8.6	—
+ Other Inflows / (Outflows) — Investing	1.6	-15.2	-197.6	-151.4	—
Cash from Investing Activities	-61.5	-149.7	-298.2	-423.7	—
Cash from Financing Activities
+ Proceeds from Borrowings	3.1	8.8	94.8	105.6	—
+ Repayment of Borrowings	116.7	48.3	39.4	44.7	—
+ Payment of Lease Liabilities	3.5	3.6	5.4	7.5	—
+ Interest Paid	12.3	13.4	7.0	17.0	—
+ Dividends Paid	6.4	12.8	18.0	15.4	—
Cash from Financing Activities	-135.8	-69.3	25.0	21.0	—
Net Changes in Cash (pre-FX)	39.9	42.2	44.2	-56.1	—
+ Effect of FX Rate Changes on Cash	0.0	0.0	0.2	0.8	—
Net Changes in Cash	39.9	42.2	44.4	-55.3	—
Closing Cash	45.4	87.6	—	76.7	—
Reference Items
EBITDA	271.8	462.6	323.3	574.5	762.9
EBITDA Margin %	22.82	29.68	21.89	28.40	32.17
Free Cash Flow (CFO − Capex)	171.1	117.5	110.9	-49.4	-49.4
Free Cash Flow to Equity	—	65.1	157.4	-5.8	—
Free Cash Flow per Basic Share	132.62	91.09	85.98	-38.27	-38.27
Cash Flow to Net Income	1.45	0.87	1.22	0.95	—
Cash Paid for Taxes	43.6	111.6	74.7	103.5	—
Cash Paid for Interest	12.3	13.4	7.0	17.0	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.